XDNA ETF

The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.

Yes, the Kelly CRISPR & Gene Editing Technology ETF does pays dividends, with the most recent payment being $0.01 per share. The last ex-dividend date was on 22 December 2022, and the next ex-dividend date has not been announced yet

As of today, Kelly CRISPR & Gene Editing Technology ETF inlcudes 24 holdings, with 21 of them being companies from 3 different countries and 1 sectors. The most weighted holdings are CRISPR Therapeutics AG (13.28%), Beam Therapeutics (11.96%) and Thermo Fisher Scientific (10.19%)

Assets under management of Kelly CRISPR & Gene Editing Technology ETF is $186 M

Average volume of Kelly CRISPR & Gene Editing Technology ETF is $3434

Expense ratio of Kelly CRISPR & Gene Editing Technology ETF is 0.78%